Premium
A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage: A pilot study
Author(s) -
Kuriya Shinichiro,
Murai Kazunori,
Miyairi Yasuro,
Utsugisawa Taiju,
Narigasawa Yasushi,
Ito Toshiharu,
Shimosegawa Kenji,
Ishida Yoji
Publication year - 1996
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19960801)78:3<422::aid-cncr7>3.0.co;2-l
Subject(s) - medicine , myelodysplastic syndromes , etoposide , cytarabine , oncology , chemotherapy , stage (stratigraphy) , leukemia , bone marrow , paleontology , biology
BACKGROUND Even now, no definitely effective therapy is inducted to high risk myelodysplastic syndromes (MDS) and their leukemic stage (MDS‐AML) except bone marrow transplantation. METHODS Ten patients with high risk MDS and 6 with MDS‐AML were treated with daily low doses of cytarabine (10 mg/m 2 /12h, infused over 2h) etoposide (50 mg/m 2 /day, infused over 2h). RESULTS Fourteen of these patients were finally evaluated among whom 6 with high risk MDS and 3 with MDS‐AML (64.3%) had complete remission, and 2 with high risk MDS (14.3%) achieved partial remission after this chemotherapy for 9 to 21 days. Three of 11 responders were resistant to the prior chemotherapies with single and low dose cytotoxic agents including cytarabine, etoposide, or aclarubicin. Although all of the patients who could be assessed developed severe marrow hypoplasia after chemotherapy, the nonhematologic side effects were mild enough to be tolerated. CONCLUSIONS This combination chemotherapy must be effective and useful in high risk MDS and MDS‐AML not only without prior chemotherapy but in cases which have been resistant to single and low dose oncostatic agent. Cancer 1996;78:422‐6.